Plain-English translation of NCT07023666 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Sickle Cell Disease research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether catching iron-related heart problems early in people with sickle cell disease—using regular heart imaging and blood tests—can prevent serious complications. Participants will receive iron chelation therapy (a medication that removes excess iron from the body) along with other heart medications based on current medical guidelines. The goal is to find these problems sooner and treat them before they cause damage.
People with sickle cell disease often receive multiple blood transfusions, which can cause dangerous levels of iron to build up in the heart. This medication and early detection approach could help prevent heart failure and other life-threatening complications before symptoms become severe.
You likely qualify if…
You likely don't qualify if…
You will visit the research clinic every 3 months for 12 months total. At each visit, you'll have heart imaging tests (including electrocardiograms, ultrasounds of your heart, and MRI scans), blood tests to check iron levels, and a physical exam. You'll also start or continue taking the iron chelation medication and other heart medications as prescribed. The research team will monitor how well the treatment is working and adjust it as needed to protect your heart health.
AI-generated summary from trial data · Sep 16, 2026 · Not medical advice
United States